Contrast-induced Nephropathy Clinical Trial
— BYPASS-CTCAOfficial title:
A Randomised Controlled Trial Assessing the Value of Computed Tomography Cardiac Angiography in Improving Patient Satisfaction and Reducing Contrast Load, Procedural Duration and Complications in Patients Who Had Previous Bypass Operation Undergoing Invasive Coronary Angiography
Verified date | December 2022 |
Source | Queen Mary University of London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A large number of patients with symptomatic ischaemic heart disease undergo coronary artery bypass grafting (CABG) to alleviate their symptoms and improve prognosis. Given the progressive nature of coronary disease, bypass grafts can narrow or block over time, leading to chest pain and the need for further invasive coronary angiography. Invasive coronary procedures in patients with bypass grafts can be more complicated due to the variation in bypass graft ostia. This can lead to longer procedure times, with higher doses of contrast and radiation and more discomfort for the patient. The aim of this study is to see if the use of computed tomography cardiac angiography (CTCA) in patients with previous bypass grafts prior to invasive coronary angiography will help make their procedure safer and quicker.
Status | Active, not recruiting |
Enrollment | 688 |
Est. completion date | September 30, 2023 |
Est. primary completion date | August 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients undergoing invasive coronary angiogram +/- percutaneous coronary Intervention 2. Previous Coronary Artery Bypass Grafting (CABG) 3. Aged =18 4. Patients able and willing to give their written informed consent. Exclusion Criteria: 1. Subjects presenting with ST elevation myocardial infarction, cardiogenic shock (systolic blood pressure <80 mmHg for >30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation. 2. Subjects with eGFR <20ml/min or on renal replacement therapy. 3. Current life-threatening condition other than vascular disease that may prevent a subject completing the study. 4. Clinical instability including cardiogenic shock, hypotension (low blood pressure-systolic blood pressure less than 90 mmHg), sustained ventricular or atrial arrhythmia requiring intravenous medications. 5. Inability to tolerate beta-blockers, including those with chronic obstructive pulmonary disease or asthma, complete heart block, second-degree atrioventricular block 6. Known contrast dye allergy. 7. Pregnancy or unknown pregnancy status. 8. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures). 9. Inability or refusal to provide informed consent. 10. Any inclusion criteria not met |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Barts Health NHS Trust | London |
Lead Sponsor | Collaborator |
---|---|
Queen Mary University of London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Procedural duration | Length of invasive coronary angiogram | Interval between administration of local anaesthesia for obtaining vascular access and removal of the last catheter | |
Primary | Incidence of Contrast Induced Nephropathy | Defined by Kidney Disease: Improving Global outcomes (KDIGO) criteria | 48-72hours | |
Primary | Patient satisfaction | Patient satisfaction measured by validated questionnaire | 4-6hours | |
Secondary | Contrast amount | Contrast amount (mls) administered during invasive coronary angiogram | From time of arterial sheath insertion to removal of arterial catheters | |
Secondary | Radiation exposure | Radiation exposure (mSv) during invasive coronary angiogram | From time of arterial sheath insertion to removal of arterial catheters | |
Secondary | Angiography related complications | Angiography related complications (coronary or aortic dissection, stroke, bleeding, vascular access complications) | 4-6hours | |
Secondary | Radial access rate | Radial access rates during invasive coronary angiogram | From time of randomisation to end of invasive coronary angiogram procedure | |
Secondary | Catheters used | Number of catheters used during invasive coronary angiogram | From time of arterial sheath insertion to removal of arterial catheters | |
Secondary | Computed Tomography Cardiac Angiography accuracy | Accuracy of the Computed Tomography Cardiac Angiography scan for detecting graft patency | From time of randomisation to end of invasive coronary angiogram procedure | |
Secondary | Number of grafts not identified | Number of grafts not identified during invasive coronary angiogram | From time of arterial sheath insertion to removal of arterial catheters | |
Secondary | Cost effectiveness of computed tomography cardiac angiography | Incremental Cost Effectiveness Ratio (ICER) | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04877847 -
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
|
N/A | |
Recruiting |
NCT02088502 -
Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy
|
Phase 2/Phase 3 | |
Completed |
NCT03329443 -
The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography
|
Phase 2 | |
Recruiting |
NCT04864847 -
Clinical Validation of the RENISCHEM L-FABP POC Assay
|
||
Completed |
NCT03627130 -
The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy
|
Phase 2 | |
Withdrawn |
NCT04603261 -
Time to Excretion of Contrast, a Maastricht Prospective Observational Study
|
||
Withdrawn |
NCT04598516 -
Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30
|
||
Recruiting |
NCT03755700 -
Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization
|
Phase 3 | |
Active, not recruiting |
NCT04606056 -
Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans
|
||
Terminated |
NCT02440646 -
Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
|
||
Completed |
NCT00175227 -
Prevention of Contrast-Induced Nephropathy
|
N/A | |
Completed |
NCT04014153 -
CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?
|
||
Withdrawn |
NCT04597892 -
Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast
|
||
Completed |
NCT03305874 -
Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization
|
||
Not yet recruiting |
NCT01871792 -
Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT06429345 -
Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.
|
Phase 4 | |
Recruiting |
NCT05271448 -
Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography
|
N/A | |
Withdrawn |
NCT03806725 -
Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography
|
||
Completed |
NCT04163250 -
Use of Urinary Cell-Cycle Arrest Biomarkers in Contrast-Associated Nephropathy After Coronary Angiography
|
||
Completed |
NCT04225013 -
Early Diagnosis as Strategy in Reducing the Incidence of Contrast-induced Nephropathy
|